Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity

Cancer Treat Rep. 1980 Jan;64(1):47-51.


Three hundred and thirty-six patients with a variety of tumors were treated with Adriamycin given weekly as an iv bolus of 1 mg/kg with subsequent doses adjusted for hematologic toxicity. This weekly schedule, not utilizing a loading course, resulted in only a 20% incidence of stomatitis. The number of evaluable patients and the percent with objective responses (respectively) according to tumor type were: lung (57 patients, 14%); sarcoma (62, 24%); breast (31, 35%); transitional cell carcinoma (17, 29%); non-Hodgkin's lymphoma (17, 29%); head and neck (16, 13%); colorectal (13, 0); ovarian (eight, 25%); and other (53, 11%). These response frequencies are comparable to those reported for every-3-week regimens using 60-75 mg/m2 of Adriamycin. Sixteen patients were given 450-550 mg/m2 of Adriamycin, five were given 550-600 mg/m2, and ten were given greater than 600 mg/m2. None of the study patients developed definite evidence of drug-induced congestive heart failure. Therefore, Adriamycin given as a weekly schedule provides a clinically effective alternative to the every-3-week schedule of administration. The weekly schedule is associated with tolerable toxicity and a decreased risk of developing drug-induced congestive heart failure.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Doxorubicin / administration & dosage*
  • Doxorubicin / adverse effects
  • Drug Administration Schedule
  • Drug Evaluation
  • Electrocardiography
  • Heart / drug effects
  • Heart Failure / chemically induced*
  • Humans
  • Injections, Intravenous
  • Leukopenia / chemically induced
  • Lung Neoplasms / drug therapy
  • Nausea / chemically induced
  • Sarcoma / drug therapy
  • Thrombocytopenia / chemically induced
  • Time Factors
  • Vomiting / chemically induced


  • Doxorubicin